Deucravacitinib (Sotyktu): First-In-Class, Allosteric Tyrosine Kinase 2 (Tyk2) Inhibitor For Adults With Moderate-To-Severe Plaque Psoriasis Approved

Rachel is a marketing graduate from the National University of Singapore. She enjoys researching and writing extensively on healthcare, medicine, and technology in her personal time. In her free time, she enjoys reading books on psychology, science-related mysteries, and documentaries as a personal interest.